Based on this pooled analysis of three prospective clinical trials in CLL, women had longer PFS than men after chemoimmunotherapy with either FCR or BR although the rate of hematological toxicities during therapy was higher.
Home / Resource Library / Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG)